| 0 | 💬 0 |
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.
(nejm.org)
|
New England Journal of Medicine 2026-02-26 | #pharmacokinetics #cancer #mutation #toxicity |